Improving management of AL amyloidosis

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 29 Nov 2023 English Publisher:Academy of Medicine, SingaporeJournal:Annals of the Academy of Medicine, Singapore, volume 52, pages 559-560 (eissn: 0304-4602,

Authors: Yuh Shan, Lee; Jeffrey, Huang;

doi: 10.47102/annals-acadmedsg.2023370

pmid: 38920144

Improving management of AL amyloidosis

- Summary
- Subjects
- Metrics

Abstract

In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges. A comprehensive review examining its pathophysiology, diagnostic approach, and management by a multidisciplinary team will set the minimum bar for treatment outcomes of patients, taking into account advances in clinical management.

Related Organizations

Keywords

Humans, Immunoglobulin Light-chain Amyloidosis, Quality Improvement

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average